Amneal Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Amneal reported Q3 2026 revenue of $863 million, up 10%, adjusted EBITDA of $207 million, up 30%, and adjusted EPS of $26 cents, up 53%.
- Affordable medicines revenue was $547 million, up 19%, driven mainly by women's health transdermal patch launches, which added 54 million, and favorable timing of a large biosimilar customer order, which added about 40 million.
- Specialty revenue was $150 million, up 20%, driven by Craxont, Brakea auto injector, and Unithroid; healthcare revenue was $165 million, down 17% as expected because of a non-repeating large product introduction in the prior-year quarter.
- Adjusted gross margin was 43.2%, up 50 basis points year over year; adjusted EBITDA growth reflected higher revenue and disciplined expense management, while adjusted EPS growth also reflected lower interest expense.
- Year-to-date revenue was up 8%, adjusted EBITDA was up 20%, and adjusted EPS was up 34%.
- Operations at the India facility affected by flooding in late July have fully resumed, and Amneal closed the Kaseeva transaction in August.
- Amneal received FDA approval for Lendriotide in September; its Q3 revenue was about $7 million following a late-September launch.
- Amneal said almost all of the 20 key launches highlighted across 2025 and 2026 are now approved and launched, and it continues to have the most CGT approvals in the US pharmaceutical industry.
- Amneal secured $60 million in tax credits from the New Jersey Economic Development Authority; a large part relates to manufacturing expansion supporting the Kaseeva acquisition and future biosimilars product roadmap.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Amneal Pharmaceuticals Third Quarter 2026 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Good morning, and thank you for joining Amneal Pharmaceuticals Third Quarter 2026 Earnings Call. Today, we issued a press release reporting Q3 results. The earnings press release and presentation are available on the IR page of amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the sections entitled "Cautionary Statements on Forward-Looking Statements" in our press release and presentation for factors that may impact future performance. We also discuss non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Chirag and Chintu Patel, co-founders and co-CEOs, Tasos Konidaris, CFO, Joe Renda for specialty, and Jason Daly, Chief Legal Officer.
I will now hand the call over to Chirag.
Thank you, Tony. Good morning, everyone. Today, Amneal is a stronger, more diversified company than ever before, with a portfolio focused on high-value products designed to drive durable growth. We've expanded across specialty, biosimilars, and complex products while building the capabilities and capacity to drive these businesses long term. 2026 marks our seventh consecutive year of top and bottom line growth, a track record that stands out in the industry. Our third quarter performance reflects that progress, with revenue of $863 million, up 10%, adjusted EBITDA of $207 million, up 30%, and adjusted EPS of $0.26, up 53%. The breadth of our portfolio and the depth of our pipeline give us confidence that we are still early in realizing Amneal's full potential. Let me highlight the progress across our key growth areas. First, in biosimilars, we closed the Kashiv transaction in Q3.
Amneal now has the end-to-end capabilities to succeed in biosimilars, R&D, manufacturing, and commercial in-house. Now it is all about execution. From a macro perspective, we have access to a large and growing biosimilar market with approximately $234 billion of U.S. biologic sales losing exclusivity over the next decade. At the same time, streamlined regulatory pathways, new commercial models such as private labels, and accelerating market adoption are creating a major inflection point for the U.S. biosimilar industry. Against this backdrop, our portfolio strategy is deliberately differentiated, balancing targeted lower competition molecules with a select number of broader biologic opportunities. We believe this approach positions Amneal to capture attractive economics and sustain long-term value creation. For Amneal, biosimilars are a natural extension of our purpose, making key medicines more accessible and affordable while building a durable growth platform.
Biologics accounts for more than half of U.S. drug spending, yet represents only 5% of total prescriptions, highlighting the significant affordability and access challenge. We believe we can help address that gap and create value for patients. Second, complex generics remains a core strength with a proven track record of execution. We have an expanding diversified portfolio of high-demand complex therapies, including women's health, transdermal patches, and important new injectable products approvals such as lanreotide, romidepsin, and iohexol. Across dosage forms, these are significant opportunities for sustained growth. We have strategically evolved our portfolio toward high-value complex products where our science, manufacturing capabilities and capacity, reliable supply, and customer relationships set us apart. Third, in specialty, our key brands are performing very well. Two years after launch, CREXONT for Parkinson's disease continues to gain share.
This is being driven by positive patient experience and compelling clinical evidence with more than three additional hours of good on time per day versus other therapies. BREKIYA is also gaining strong traction in migraine and cluster headache, performing ahead of our expectations this year. We see our specialty segment becoming considerably large over time. Fourth, AvKARE remains important aspect of our business that provides diversification and access to government and institutional channels for our high-value products, including biosimilars in the future. Fifth, we are advancing our GLP-1 collaboration with Pfizer, as construction of our new dedicated GLP-1 manufacturing facilities for both drug substance and drug product remain on track for 2028. Taken together, Amneal has a fundamentally stronger and more diversified growth profile than ever before, with more growth engines, more innovation, and more opportunities ahead.
Our focus is on the execution, delivering across each of these areas, converting that potential into results. We believe the momentum of 2026 positions us very well for continued high growth in 2027 and beyond. With that, I'll turn it over to Chintu.
Thank you, Chirag, and good morning, everyone. I want to thank the entire Amneal team, which continues to execute at a high level. Their strong performance enables us to pursue increasingly ambitious opportunities while continuing to deliver across our existing businesses. Since our last call, we closed the Kashiv transaction in August. The combined team is working as one across development, manufacturing, and commercialization to build our biosimilar business. As we shared on our Q2 call, one of our India facilities experienced flooding back in late July. The team worked tirelessly to limit the impact, and we are pleased to share that operations have fully resumed. In addition, in September, we received FDA approval for lanreotide, a high-value complex injectable. Let me focus on four areas. First, integrating Kashiv and advancing our biosimilar pipeline. Second, our global operational strategy. Third, our R&D portfolio. And fourth, growing our specialty business.
First, in biosimilar, we now have the end-to-end capabilities, from cell line and clone development to clinical execution, regulatory expertise, biologics manufacturing, and commercialization. Kashiv brings the science, development, and biologics manufacturing, while Amneal brings commercial scale, channel expertise, and customer relationships. Together, we can move faster, plan effectively, and capture more value, reinforcing biosimilars as a key long-term growth pillar for Amneal. The combined platform is designed to make disciplined portfolio decisions, advance multiple molecules in parallel, and create a repeatable path from R&D through commercialization. Our biosimilars manufacturing footprint in New Jersey and India is expanding, which enables us to work on a growing number of biosimilar R&D programs and also meet commercial demand. Our biosimilars pipeline is focused on early-to-market global opportunities, where we are targeting being first or second to launch.
We built this playbook and executed it well in complex generics, and we are now applying it to biosimilars. Second, in operations, our priorities remain clear: quality, reliability, and resiliency. Across our global manufacturing and supply chain network, we continue to deepen our capabilities and capacity in complex generics, sterile injectables, and biosimilars. Our facilities have transformed in recent years through digitization, automation, and AI-enabled tools. We are advancing our manufacturing capabilities and quality while improving efficiency. At the same time, we are scaling capacity for our key growth areas, including significant expansion for women's health transdermal patches this year, new U.S. sterile injectable capabilities by 2028, expanding our complex injectable capacity for key programs like lanreotide and risperidone, building out our two new GLP-1 facilities, and increasing biosimilar capacity to support our pipeline. These initiatives are designed to meet increasing market demand and drive meaningful new growth.
This broad operational platform is differentiated in the industry. Our large manufacturing footprint across 20 global facilities and technical expertise position Amneal well to deliver reliable supply, address important market needs, and pursue new growth opportunities at the same time. Third, turning to our complex generics pipeline, we continue to convert many years of R&D hard work into significant commercial products. Complex generics build this company, and we are not slowing down. That strategy is visible in the differentiated portfolio, spanning injectables, ophthalmics, inhalation, transdermal, drug device combinations, 505(b)(2) products, and other dosage forms. Recent approvals are important proof points. Recent approvals include key complex generics and 505(b)(2) products, such as lanreotide, romidepsin RTU, sodium bicarbonate IV bag, and additional strengths and presentations of iohexol. These products expand our portfolio into large, attractive markets and demonstrate our ability to develop, manufacture, and commercialize increasingly complex medicines in-house.
Looking ahead, we are advancing a deep pipeline of long-acting injectable, 505(b)(2), and inhalation programs. We continue to have the most CGT approvals in the U.S. pharmaceutical industry. One year ago, on our Q3 call, we highlighted 20 key launches across 2025 and 2026 that we believed would propel our affordable medicines business to a new level. Today, almost all are now approved and launched. Looking forward, we see a next wave of new product launch opportunities between 2027 and 2029, particularly new sterile injectables and bag products. This gives us high confidence that growth in affordable medicines will continue to stay elevated in the years ahead. Importantly, this is not a one-time launch cycle. It reflects the innovation engine we have built over many years and the steady conversion of those programs into successful commercial launches.
Specifically, inhalation is a new growth platform that we have been building. Last year, we received our first two approvals, PROAIR and QVAR. Looking ahead, we are targeting five additional MDI and soft mist approvals over the next three years. We see inhalation as a new vector of growth for the business. Fourth, in specialty, we are very pleased with the continued performance of CREXONT and BREKIYA. The strength is visible not only in higher revenues, but also in prescription trends, physician adoption, and the growing number of patients benefiting from these impactful therapies. For CREXONT, we continue to build on the clinical and real-world evidence supporting its differentiated profile in Parkinson's disease treatment landscape. We are pursuing second phase IV study, evaluating its effect on disease progression.
As awareness and physician experience expand, the opportunity remains clear to expand CREXONT's reach among the 700,000 patients in the U.S. on carbidopa-levodopa therapy. Beyond CREXONT and BREKIYA, we are advancing additional 505(b)(2) and novel R&D programs to build a broader specialty platform focused on differentiated medicines that improve patient outcomes. Across our businesses, our formula remains the same: strong science, quality first, robust planning, care for customers and patient, and disciplined execution. The progress made in 2026 and the catalyst ahead gives us very strong confidence heading into 2027. With that, I will turn it over to Tasos.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
